-
1
-
-
11144355354
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
-
Erratum in: N Engl J Med 2006;354(7):778
-
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504. Erratum in: N Engl J Med 2006;354(7):778.
-
(2004)
N Engl J Med
, vol.350
, Issue.15
, pp. 1495-504
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
Rader, D.J.4
Rouleau, J.L.5
Belder, R.6
-
2
-
-
0035897696
-
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
-
(2001)
JAMA
, vol.285
, Issue.19
, pp. 2486-2497
-
-
-
3
-
-
0037031061
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [summary for patients in Curr Cardiol Rep 2002;4(6):486-7]
-
Heart Protection Study Collaborative Group
-
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [summary for patients in Curr Cardiol Rep 2002;4(6):486-7]. Lancet 2002;360(9326):7-22.
-
(2002)
Lancet
, vol.360
, Issue.9326
, pp. 7-22
-
-
-
4
-
-
0037420492
-
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
-
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58.
-
(2003)
Lancet
, vol.361
, Issue.9364
, pp. 1149-1158
-
-
Sever, P.S.1
Dahlöf, B.2
Poulter, N.R.3
Wedel, H.4
Beevers, G.5
Caulfield, M.6
-
5
-
-
0037164314
-
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
-
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623-30.
-
(2002)
Lancet
, vol.360
, Issue.9346
, pp. 1623-1630
-
-
Shepherd, J.1
Blauw, G.J.2
Murphy, M.B.3
Bollen, E.L.4
Buckley, B.M.5
Cobbe, S.M.6
-
6
-
-
0042832397
-
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
-
Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37(5):613-27.
-
(2003)
Clin Infect Dis
, vol.37
, Issue.5
, pp. 613-627
-
-
Dubé, M.P.1
Stein, J.H.2
Aberg, J.A.3
Fichtenbaum, C.J.4
Gerber, J.G.5
Tashima, K.T.6
-
7
-
-
3042848853
-
Efficacy and safety of tenofovir DF vs stavuine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
-
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavuine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292 (2):191-201.
-
(2004)
JAMA
, vol.292
, Issue.2
, pp. 191-201
-
-
Gallant, J.E.1
Staszewski, S.2
Pozniak, A.L.3
DeJesus, E.4
Suleiman, J.M.5
Miller, M.D.6
-
8
-
-
17844387166
-
Atazanavir plus ritonavir or saquinavir and lopinavir/ritonavir in patients experiencing multiple virological failures
-
Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19(7):685-94.
-
(2005)
AIDS
, vol.19
, Issue.7
, pp. 685-694
-
-
Johnson, M.1
Grinsztejn, B.2
Rodriguez, C.3
Coco, J.4
DeJesus, E.5
Lazzarin, A.6
-
9
-
-
69449092725
-
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
-
Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23(13):1679-88.
-
(2009)
AIDS
, vol.23
, Issue.13
, pp. 1679-1688
-
-
Mills, A.M.1
Nelson, M.2
Jayaweera, D.3
Ruxrungtham, K.4
Cassetti, I.5
Girard, P.M.6
-
10
-
-
77649201378
-
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study
-
Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study. J Acquir Immune Defic Syndr 2010;53(3):323-32.
-
(2010)
J Acquir Immune Defic Syndr
, vol.53
, Issue.3
, pp. 323-332
-
-
Molina, J.M.1
Andrade-Villanueva, J.2
Echevarria, J.3
Chetchotisakd, P.4
Corral, J.5
David, N.6
-
11
-
-
33847126560
-
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
-
Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44(2):139-47.
-
(2007)
J Acquir Immune Defic Syndr
, vol.44
, Issue.2
, pp. 139-147
-
-
Podzamczer, D.1
Ferrer, E.2
Sanchez, P.3
Gatell, J.M.4
Crespo, M.5
Fisac, C.6
-
12
-
-
43149106498
-
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the inital treatment of HIV infection: 48-week results of ALERT
-
Smith KY, Weinberg WG, DeJesus E, Fischl MA, Liao Q, Ross LL, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the inital treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5(5):1-10.
-
(2008)
AIDS Res Ther
, vol.5
, Issue.5
, pp. 1-10
-
-
Smith, K.Y.1
Weinberg, W.G.2
DeJesus, E.3
Fischl, M.A.4
Liao, Q.5
Ross, L.L.6
-
13
-
-
15744367156
-
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
-
Erratum in: PLoS Med 2004;1(3):e73
-
van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 . PLoS Med 2004;1(1):e19. Erratum in: PLoS Med 2004;1(3):e73.
-
(2004)
PLoS Med
, vol.1
, Issue.1
-
-
van Leth, F.1
Phanuphak, P.2
Stroes, E.3
Gazzard, B.4
Cahn, P.5
Raffi, F.6
-
14
-
-
64249163753
-
Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults
-
Walmsley S, Avihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009;50(4):367-74.
-
(2009)
J Acquir Immune Defic Syndr
, vol.50
, Issue.4
, pp. 367-374
-
-
Walmsley, S.1
Avihingsanon, A.2
Slim, J.3
Ward, D.J.4
Ruxrungtham, K.5
Brunetta, J.6
-
16
-
-
20644459485
-
Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure
-
Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;10;19(9):927-33.
-
(2005)
AIDS
, vol.10-19
, Issue.9
, pp. 927-933
-
-
Currier, J.S.1
Kendall, M.A.2
Zackin, R.3
Henry, W.K.4
Alston-Smith, B.5
Torriani, F.J.6
-
17
-
-
17144463863
-
Severe premature coronary artery disease with protease inhibitors
-
Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351(9112):1328.
-
(1998)
Lancet
, vol.351
, Issue.9112
, pp. 1328
-
-
Henry, K.1
Melroe, H.2
Huebsch, J.3
Hermundson, J.4
Levine, C.5
Swensen, L.6
-
18
-
-
34848856661
-
Ten-year predicted coronary heart disease risk in HIV-infected men and women
-
Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007;45(8):1074-81.
-
(2007)
Clin Infect Dis
, vol.45
, Issue.8
, pp. 1074-1081
-
-
Kaplan, R.C.1
Kingsley, L.A.2
Sharrett, A.R.3
Li, X.4
Lazar, J.5
Tien, P.C.6
-
19
-
-
39349094372
-
Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms
-
Lai S, Fishman EK, Lai H, Moore R, Cofranchesco JJ Jr, Pannu H, et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Clin Infect Dis 2008;46:600-10.
-
(2008)
Clin Infect Dis
, vol.46
, pp. 600-610
-
-
Lai, S.1
Fishman, E.K.2
Lai, H.3
Moore, R.4
Cofranchesco Jr., J.J.5
Pannu, H.6
-
20
-
-
0042768569
-
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population
-
Savès M, Chène G, Ducimetière P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37(2):292-8.
-
(2003)
Clin Infect Dis
, vol.37
, Issue.2
, pp. 292-298
-
-
Savès, M.1
Chène, G.2
Ducimetière, P.3
Leport, C.4
Le Moal, G.5
Amouyel, P.6
-
21
-
-
34250671221
-
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
-
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92(7):2506- 12.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, Issue.7
, pp. 2506-2512
-
-
Triant, V.A.1
Lee, H.2
Hadigan, C.3
Grinspoon, S.K.4
-
22
-
-
36348984420
-
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection
-
Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21(18):2445-53.
-
(2007)
AIDS
, vol.21
, Issue.18
, pp. 2445-2453
-
-
Wand, H.1
Calmy, A.2
Carey, D.L.3
Samaras, K.4
Carr, A.5
Law, M.G.6
-
23
-
-
0032493043
-
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
-
Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-8.
-
(1998)
AIDS
, vol.12
, Issue.7
-
-
Carr, A.1
Samaras, K.2
Burton, S.3
Law, M.4
Freund, J.5
Chisholm, D.J.6
-
24
-
-
0033583977
-
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
-
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093-9.
-
(1999)
Lancet
, vol.353
, Issue.9170
, pp. 2093-2099
-
-
Carr, A.1
Samaras, K.2
Thorisdottir, A.3
Kaufmann, G.R.4
Chisholm, D.J.5
Cooper, D.A.6
-
25
-
-
33746706779
-
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
-
Eron J, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368(9534):476-82.
-
(2006)
Lancet
, vol.368
, Issue.9534
, pp. 476-482
-
-
Eron, J.1
Yeni, P.2
Gathe Jr., J.3
Estrada, V.4
DeJesus, E.5
Staszewski, S.6
-
26
-
-
17044457456
-
Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens
-
Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003;33(5):594-600.
-
(2003)
J Acquir Immune Defic Syndr
, vol.33
, Issue.5
, pp. 594-600
-
-
Gutiérrez, F.1
Padilla, S.2
Navarro, A.3
Masiá, M.4
Hernández, I.5
Ramos, J.6
-
27
-
-
17844387166
-
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures [republished from AIDS 2005;19(2):153-62]
-
Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures [republished from AIDS 2005;19(2):153-62]. AIDS 2005;19(7):685-94.
-
(2005)
AIDS
, vol.19
, Issue.7
, pp. 685-694
-
-
Johnson, M.1
Grinsztejn, B.2
Rodriguez, C.3
Coco, J.4
DeJesus, E.5
Lazzarin, A.6
-
28
-
-
11144357725
-
Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir
-
Martínez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004;38(7):1017-23.
-
(2004)
Clin Infect Dis
, vol.38
, Issue.7
, pp. 1017-1023
-
-
Martínez, E.1
Domingo, P.2
Galindo, M.J.3
Milinkovic, A.4
Arroyo, J.A.5
Baldovi, F.6
-
29
-
-
1642403331
-
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIVinfected men
-
Clinical Epidemiology Group from the French Hospital Database
-
Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIVinfected men. AIDS 2003;17(17):2479-86.
-
(2003)
AIDS
, vol.17
, Issue.17
, pp. 2479-2486
-
-
Mary-Krause, M.1
Cotte, L.2
Simon, A.3
Partisani, M.4
Costagliola, D.5
-
30
-
-
21044446635
-
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors
-
Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005;55(5):800-4.
-
(2005)
J Antimicrob Chemother
, vol.55
, Issue.5
, pp. 800-804
-
-
Montes, M.L.1
Pulido, F.2
Barros, C.3
Condes, E.4
Rubio, R.5
Cepeda, C.6
-
31
-
-
0034005969
-
Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
-
Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23(1):35-43.
-
(2000)
J Acquir Immune Defic Syndr
, vol.23
, Issue.1
, pp. 35-43
-
-
Mulligan, K.1
Grunfeld, C.2
Tai, V.W.3
Algren, H.4
Pang, M.5
Chernoff, D.N.6
-
32
-
-
36348983244
-
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain
-
Simpson KN, Jones WJ, Rajagopalan R, Dietz B. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig 2007;27(12):807-17.
-
(2007)
Clin Drug Investig
, vol.27
, Issue.12
, pp. 807-817
-
-
Simpson, K.N.1
Jones, W.J.2
Rajagopalan, R.3
Dietz, B.4
-
33
-
-
0037805278
-
Impact of HIV infection and HAART on serum lipids in men
-
Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289(22):2978-82.
-
(2003)
JAMA
, vol.289
, Issue.22
, pp. 2978-2982
-
-
Riddler, S.A.1
Smit, E.2
Cole, S.R.3
Li, R.4
Chmiel, J.S.5
Dobs, A.6
-
34
-
-
0017384270
-
High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
-
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62(5):707-14.
-
(1977)
Am J Med
, vol.62
, Issue.5
, pp. 707-714
-
-
Gordon, T.1
Castelli, W.P.2
Hjortland, M.C.3
Kannel, W.B.4
Dawber, T.R.5
-
35
-
-
4444348746
-
Characteristics of US adults with the metabolic syndrome and therapeutic implications
-
Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JC, et al. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab 2004;6(5):353-62.
-
(2004)
Diabetes Obes Metab
, vol.6
, Issue.5
, pp. 353-362
-
-
Jacobson, T.A.1
Case, C.C.2
Roberts, S.3
Buckley, A.4
Murtaugh, K.M.5
Sung, J.C.6
-
36
-
-
4544275379
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
-
Grundy SM, Cleeman JI, Merz CN, Brewer HP Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44(3):720-32.
-
(2004)
J Am Coll Cardiol
, vol.44
, Issue.3
, pp. 720-732
-
-
Grundy, S.M.1
Cleeman, J.I.2
Merz, C.N.3
Brewer Jr., H.P.4
Clark, L.T.5
Hunninghake, D.B.6
-
37
-
-
33644836728
-
Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia
-
Persell SD, Lloyd-Jones DM, Baker DW. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med 2006;21(2):171-6.
-
(2006)
J Gen Intern Med
, vol.21
, Issue.2
, pp. 171-176
-
-
Persell, S.D.1
Lloyd-Jones, D.M.2
Baker, D.W.3
-
38
-
-
42549106562
-
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction
-
Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, et al.
-
Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, et al. . Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008;46 (7):1101-10.
-
(2008)
Clin Infect Dis
, vol.46
, Issue.7
, pp. 1101-1110
-
-
-
39
-
-
84863226094
-
Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study
-
Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol 2012;19(2):267-74.
-
(2012)
Eur J Prev Cardiol
, vol.19
, Issue.2
, pp. 267-274
-
-
Reinsch, N.1
Neuhaus, K.2
Esser, S.3
Potthoff, A.4
Hower, M.5
Mostardt, S.6
-
40
-
-
42649130015
-
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
-
D:A:D Study Group; Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al.
-
D:A:D Study Group; Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. . Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622);1417-26.
-
(2008)
Lancet
, vol.371
, Issue.9622
, pp. 1417-1426
-
-
-
41
-
-
47049111149
-
Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study
-
Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008;48(3):272-80
-
(2008)
J Acquir Immune Defic Syndr
, vol.48
, Issue.3
, pp. 272-278
-
-
Sobieszczyk, M.E.1
Hoover, D.R.2
Anastos, K.3
Mulligan, K.4
Tan, T.5
Shi, Q.6
|